Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B ‐ authors' reply

WenXian OuYang,ShuangJie Li,Songxu Peng

DOI: https://doi.org/10.1111/apt.17843

IF: 9.524

2024-01-12

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 59, Issue 3, Page 425-426, February 2024.

pharmacology & pharmacy,gastroenterology & hepatology

What problem does this paper attempt to address?

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B

Jing Li,Yaxin Wu,Fu‐Sheng Wang

DOI: https://doi.org/10.1111/apt.17830

IF: 9.524

2024-01-12

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 59, Issue 3, Page 423-424, February 2024.

pharmacology & pharmacy,gastroenterology & hepatology
The Impact of Early Rapid Virological Response on the Outcomes of Hepatitis B Associated Acute on Chronic Liver Failure During Antiviral Treatment

Li Chen,Cai-xia Zheng,Ming-hua Lin,Qiao-rong Gan,Rong-sheng Lin,Hai-bing Gao,Jian-rong Huang,Chen Pan

DOI: https://doi.org/10.3760/cma.j.issn.1007-3418.2011.10.004

2011-01-01

Abstract:OBJECTIVE:To investigate the impact of early rapid virological response on the outcomes of hepatitis B associated acute on chronic liver failure during antiviral treatment.METHODS:106 acute on chronic liver failure patients in our hospital from January 2008 to July 2010 were enrolled in present study retrospectively. Besides internal medicine therapy, all patients received lamivudine (100 mg/d) or entecavir (0.5 mg/d) treatment. The profile of liver biochemistry, prothrombin time activity and viral load were detected at baseline and week 4, respectively. The patients were divided into HBV DNA negative group and HBV DNA positive group according to the viral load at week 4. The clinical features and treatment outcomes were compared between groups. Frequency variables were compared by x2 test or Fisher's exact test. Continuous variables were compared using independent samples T-test. The factors that impact on the treatment outcomes were determined using stepwise multivariate logistic regression analysis.RESULTS:At the week 4, the TBil and PTA in HBV DNA positive group [(261.6+/-205.6)mumol/L and 44.7%+/-19.7%, respectively] were significantly different from those in HBV DNA negative group [(160.1+/-173.4) mumol/L and 56.8%+/-23.1%, respectively] ( t = 2.190 and -2.077, respectively, P less than 0.05). The non-effective rate of HBVDNA positive group (50%, 9/18) was significantly higher than that of HBV DNA negative group (14.8%, 13/88) (x2 = 9.235, P less than 0.01). By using stepwise multivariate logistic regression analysis, the disease stage and HBV DNA undetectable at week 4 were the independent factor. The OR values of disease stage and HBV DNA undetectable were 6.559 and 0.209, respectively, and 95% CI was 2.316~18.576 and 0.058~0.747, respectively.CONCLUSION:The rapid suppression of viral load by nucleotide analogue may improve the efficacy of hepatitis B associated acute on chronic liver failure treatment. The early rapid virological response within first 4 weeks may contribute to the prediction of the treatment outcomes.
Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B.

Rui Yu,Deming Tan,Qin Ning,Junqi Niu,Xuefan Bai,Shijun Chen,Jun Cheng,Yanyan Yu,Hao Wang,Min Xu,Guangfeng Shi,Mobin Wan,Xinyue Chen,Hong Tang,Jifang Sheng,Xiaoguang Dou,Junping Shi,Hong Ren,Maorong Wang,Hongfei Zhang,Zhiliang Gao,Chengwei Chen,Hong Ma,Jidong Jia,Jinlin Hou,Qing Xie,Jian Sun

DOI: https://doi.org/10.1111/hepr.12972

2018-01-01

Hepatology Research

Abstract:Aim: The role of vitamin D in individuals with chronic hepatitis B (CHB) is unclear. We aimed to explore the association of baseline vitamin D level with genetic determinants and week-104 treatment outcome in CHB patients. Methods: Baseline serum 25-hydroxycholecalciferol (25(OH)D) levels and genetic polymorphism within GC, DHCR7, and CYP2R1 were determined in stored serum of 560 patients who were enrolled into amulticenter, randomized, controlled study and completed 104 weeks of telbivudine monotherapy or telbivudine-based optimized therapy. Virologic response was defined as hepatitis B virus DNA <300 copies/mL (52 IU/mL) at week 104. Results: The mean 25(OH)D value was 29.64 ng/mL. The percentage of patients with vitamin D insufficiency (<30 ng/mL) and vitamin D deficiency (<20 ng/mL) were 55.0% and 20.9%, respectively. Gender, season, latitude, and GC rs2282679 polymorphism were independent factors of vitamin D status. Patients with sufficient vitamin D (>= 30 ng/mL) achieved a higher virologic response rate than those with vitamin D insufficiency (81.7% vs. 67.2%, P < 0.001). The area under the curve of 25(OH)D to predict virologic response was 0.65 (P < 0.001; 95% confidence interval, 0.62-0.67). On multivariate analysis, 25(OH)D level was an independent predictor of virologic response, but not associated with hepatitis B envelope antigen (HBeAg) seroconversion or alanine aminotransferase (ALT) normalization. Conclusions: Vitamin D insufficiency was highly prevalent in treatment-naive CHB patients in mainland China. Latitude and genetic determinants affect vitamin D status. Baseline vitamin D level can predict week-104 virologic response, but not HBeAg seroconversion or ALT normalization.
Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments—Authors' reply

Hyeyeon Hong,Jonggi Choi

DOI: https://doi.org/10.1111/apt.17875

IF: 9.524

2024-01-22

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 59, Issue 4, Page 588-588, February 2024.

pharmacology & pharmacy,gastroenterology & hepatology
Efficacy and safety of interferon alpha therapy in children with chronic hepatitis B: A long-term follow-up cohort study from China.

Yao Hu,Yingzi Ye,Lijing Ye,Xiaohong Wang,Hui Yu

DOI: https://doi.org/10.1097/MD.0000000000016683

IF: 1.6

2019-01-01

Medicine

Abstract:Interferon-alpha (IFN-alpha) is currently the preferred antiviral treatment for children with chronic hepatitis B (CHB) aged >1-year-old. However, the evidence regarding the exact efficacy and safety in the real world is not sufficient. This study aimed to investigate the efficacy of IFN-alpha therapy in children with CHB and to provide a theoretical basis for practically identifying ideal antiviral therapies for CHB children. Clinical manifestations, baseline characteristics, related laboratory tests, and adverse events were retrospectively analyzed in children with CHB who visited the Children's Hospital of Fudan University, were treated with IFN-alpha and were followed up from January 2003 to October 2018. A total of 18 immune-active patients without advanced fibrosis were enrolled, and their average age at the start of treatment was 4.45 +/- 2.75 years old. IFN alpha-2b was administered subcutaneously by body surface area (BSA) category, based on 3MU/m(2), for a median 48 weeks. Before treatment, the alanine aminotransferase (ALT) range was 81 to 409U/L (median 158U/L). The median hepatitis B virus (HBV)-DNA load was 9.89 x 10(7) IU/mL, and the HBV-DNA load varied from 3.10 x 10(4) to 4.56 x 10(8) IU/mL. The ALT levels of 17 children became normal at an average of 12 weeks during treatment, and those of 1 child became normal at 6 weeks after IFN-alpha withdrawal. Sixteen (88.9%, 16/18) children became HBV-DNA negative (<10(3) IU/mL) at an average of 24 weeks during treatment, while 1 became negative at 96 weeks after IFN-alpha withdrawal and 1 remained HBV-DNA positive. HBV e antigen (HBeAg) seroconversion occurred in 13 of 14 (92.9%, 13/14) HBeAg-positive patients at an average of 12 weeks during treatment. HBV s antigen (HBsAg) loss or seroconversion occurred in 4 (22.2%, 4/18) patients at an average of 21 weeks during treatment. Only mild flu-like symptoms and transient neutropenia appeared in some children at the early treatment stage. No severe abnormal results were observed in other laboratory parameters. The antiviral monotherapy of 48 weeks of IFN-alpha was well tolerated and good responded, which was associated with higher rates of HBeAg seroconversion and HBsAg clearance in the children in this study than in previously reported adults and pediatric patients.
Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B

Jian Wang,Tao Fan,Shaoqiu Zhang,Chao Wu,Rui Huang

DOI: https://doi.org/10.1111/apt.17922

IF: 9.524

2024-03-25

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 59, Issue 8, Page 1012-1013, April 2024.

pharmacology & pharmacy,gastroenterology & hepatology
Association Between Negative Results from Tests for HBV DNA and RNA and Durability of Response after Discontinuation of Nucles(t)ide Analogue Therapy.

Rong Fan,Bin Zhou,Min Xu,Deming Tan,Junqi Niu,Hao Wang,Hong Ren,Xinyue Chen,Maorong Wang,Qin Ning,Guangfeng Shi,Jifang Sheng,Hong Tang,Xuefan Bai,Shi Liu,Fengmin Lu,Jie Peng,Jian Sun,Qing Xie,Jinlin Hou,Mobin Wan,Shijun Chen,Yanyan Yu,Hong Ma,Jun Cheng,Hongfei Zhang,Huimin Liu,Zhiliang Gao,Sun Yat-Sen,Xiaoguang Dou

DOI: https://doi.org/10.1016/j.cgh.2019.07.046

IF: 13.576

2019-01-01

Clinical Gastroenterology and Hepatology

Abstract:BACKGROUND & AIMS: There is no satisfactory way to identify patients who will maintain a response after discontinuation of nuleos(t)ide analogue therapy for chronic hepatitis B virus (HBV) infection. We investigated whether patients with negative results from tests for HBV DNA and HBV RNA (double negative) at the end of treatment maintain a long-term response to treatment. METHODS: We performed a post-hoc analysis of data from a 2-year multi-center randomized controlled trial, and its long-term extension trials, on 130 patients with chronic HBV infection who were positive for the HB e antigen (HBeAg-positive; mean age, 30.8 +/- 6.9 years; 72.3% male) and received telbivudine with or without adefovir and stopped therapy after they had HBeAg seroconversion and levels of HBV DNA <300 copies/mL for at least 48 weeks (evaluation cohort). Clinical and laboratory assessments were made every 12 or 16 weeks until clinical relapse (defined as HBV DNA > 2000 IU/mL and level of alanine aminotransferase more than 2-fold the upper limit of normal) or until 4 years off treatment. We validated our findings in a cohort of 40 HBeAg-positive patients (36.5 +/- 9.4 years old; 72.5% male) treated with entecavir or tenofovir, and followed after discontinuation for up to 5.5 years. Patients were considered to be negative for HBV DNA if it was not detected in the COBAS Taqman assay. Patients were considered to be negative for HBV RNA if it was not detected by quantitative real-time PCR with 2 different pairs of primers. RESULTS: After 4 years off treatment, in the evaluation cohort, 30.8% of patients had a clinical relapse, 54.7% had virologic relapse (HBV DNA >2000 IU/mL in 2 tests), and 16.8% had reappearance of HBeAg in 2 tests (reversion). A significantly lower proportion of double negative patients had a clinical relapse 4 years later (2/35; 8.0%) than of patients who tested positive for either HBV DNA or RNA (32/102; 31.4%; P = .018). In the validation cohort, after 5.5 years of follow up, a lower proportion of double negative patients had clinical relapse (2/13; 15.4%) than of patients who tested positive for either HBV DNA or RNA at the end of treatment (9/27; 33.3%; P = .286) CONCLUSIONS: In an analysis of data from 2 independent cohorts, we associated negative results from tests for HBV DNA and RNA (double negative) at the end of treatment with continued response 4 or more years after discontinuation of therapy in HBeAg-positive patients. These results might be used to identify the best candidates for discontinuation of nuleos(t)ide analogue therapy.
Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir

J.-H. Xu,L.-W. Song,N. Li,S. Wang,Zheng Zeng,C.-W. Si,J. Li,Q. Mao,D.-Z. Zhang,Hong Tang,Jifang Sheng,X.-Y. Chen,Qin Ning,Guangfeng Shi,Q. Xie,Quan Yuan,Yanyan Yu,Ningshao Xia

DOI: https://doi.org/10.1111/jvh.12626

2017-01-01

Journal of Viral Hepatitis

Abstract:Studies regarding the clinical significance of quantitative hepatitis B core antibody (anti-HBc) in patients with chronic hepatitis B receiving first-line nucleos(t) ide analogues is limited. The aim of this study was to determine the performance of anti-HBc as a predictor for hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive CHB patients treated with entecavir. This was a retrospective cohort study consisting of 139 Chinese patients enrolled in a multicenter clinical trial treated with entecavir or entecavir maleate for up to 240 weeks. Anti-HBc evaluation was conducted for all the available samples using a newly developed double-sandwich anti-HBc immunoassay. At week 240, 35 (25.2%) patients achieved a serological response (HBeAg seroconversion) and these patients at week 240 had significantly higher levels of anti-HBc (P<.01). We defined 4.65 log(10) IU.mL(-1), with a maximum sum of sensitivity and specificity, as the optimal cut-off value of baseline anti-HBc level to predict seroconversion. Patients with baseline anti-HBc >= 4.65 log(10) IU.mL(-1) had 28.0% (26/93) and 35.5% (33/93) chance of seroconversion at weeks 144 and 240, respectively. The baseline anti-HBc level was the strongest predictor for seroconversion at week 144 (OR: 5.78, 95% confidence interval [CI]: 2.05-16.34, P=.001). The baseline anti-HBc level was a strong predictor for seroconversion at week 240 (OR: 5.36, 95% CI: 2.17-13.25, P<.001). Hence, baseline anti-HBc titre is a useful predictor of long-term entecavir therapy efficacy in HBeAg-positive CHB patients, which could be used to optimize antiviral therapy.
Editorial: baseline hepatitis B virus haplotype number may help predict a functional cure in patients with chronic hepatitis B treated with nucleotide analogues—authors' reply

Josef Wagner,Margaret Littlejohn,Peter A. Revill

DOI: https://doi.org/10.1111/apt.17364

2023-02-15

Abstract:Alimentary Pharmacology &Therapeutics, Volume 57, Issue 5, Page 583-584, March 2023.

pharmacology & pharmacy,gastroenterology & hepatology
Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan

Hong-Yuan Hsu,Hsiu-Yuan Tsai,Tzee-Chung Wu,Cheng-Lun Chiang,Yen-Hsuan Ni,Pei-Jer Chen,Mei-Hwei Chang

DOI: https://doi.org/10.1111/j.1478-3231.2008.01746.x

Abstract:Background/aims: The short- and long-term benefits of interferon (IFN)-alpha therapy in young patients with chronic hepatitis B (CHB) acquiring infection perinatally or during early childhood have been questioned. Methods: Twenty-one Taiwanese hepatitis B envelope antigen (HBeAg)-positive CHB patients aged 1.8-21.8 years (median 14.0 years) with alanine aminotransferase (ALT)>80 IU/L at entry were enrolled for IFN-alpha therapy. They received IFN-alpha therapy with a dose of 3 MU/m(2)/day three times a week for 24 weeks. A control group included untreated 21 CHB patients closely matched for gender, age, duration of ALT >80 IU/L and HBeAg status. All 42 patients were prospectively followed for 6.5-12.5 years after the end of therapy. Results: The cumulative rate of virological response [anti-HBe seroconversion and serum hepatitis B virus (HBV)-DNA <10(5) copies/ml] was not different between the IFN-treated patients and control patients at 1 year (41 vs 44%) and at 6 years (88 vs 89%) after stopping treatment. Serum hepatitis B surface antigen loss occurred in two (9.5%) treated patients and in one (4.8%) control patient. Patients with a successful treatment response (anti-HBe seroconversion, HBV-DNA <10(2) copies/ml and ALT normalization at 1 year after stopping treatment) were younger than those without a successful response (P=0.03). A lower pretreatment serum HBV-DNA level (<2 x 10(8) copies/ml) is not only a significant factor to predict successful treatment response (P=0.008) but also has a beneficial effect on the long-term cumulative rate of virological response in IFN-treated patients (P=0.021), but not in control patients. Genotype difference or emergence of a precore stop codon mutant before treatment was not predictive for HBeAg clearance. Conclusion: For young CHB patients in Taiwan with infection occurring perinatally or in early childhood, the real advantage of IFN-alpha therapy was not observed. IFN-alpha therapy showed a beneficial effect on short- and long-term virological outcomes only in those with a lower pretreatment serum HBV-DNA level.
Letter: improved alanine aminotransferase level in non-cirrhotic and low-viral load chronic hepatitis B patients treated with nucleotide/nucleoside analogues -authors' reply

Rui Huang,Jian Wang,Xiaomin Yan,Chuanwu Zhu,Chao Wu

DOI: https://doi.org/10.1111/apt.17367

IF: 9.524

2023-01-01

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Wang et al papers. To view these articles, visit https://doi.org/10.1111/apt.17272 and https://doi.org/10.1111/apt.17329
Letter: Programmed Death-1-a Predictor for Antiviral Treatment in Chronic Hepatitis B. Authors' Reply.

Rui Huang,Juan Xia,Jian Wang,Yuxin Chen,Chao Wu

DOI: https://doi.org/10.1111/apt.15924

IF: 9.524

2020-01-01

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENTThis article is linked to the Xia et al and Vyas papers. To view these articles, visit https://doi.org/10.1111/apt.15732 and https://doi.org/10.1111/apt.15878
The Effect of Highly Active Antiretroviral Therapy on Liver Function in Human Immunodeficiency Virus-Infected Pediatric Patients with or Without Hepatitis Virus Co-Infection

Lijuan Wu,Changzhong Jin,Shi Bai,Henry Davies,Heping Rao,Yong Liang,Nanping Wu

2015-01-01

Abstract:Background: Co-infection of hepatitis virus is common in human immunodeficiency virus (HIV) infected adults in China. But little is known about hepatitis virus co-infection in pediatric HIV-infected subjects. The study aimed to investigate the impact of hepatitis B virus (HBV) and/or hepatitis C virus (HCV) co-infection and highly active antiretroviral therapy (HAART) on liver function of pediatric HIV-infected subjects. Materials and Methods: A cohort study including 101 pediatric HIV-infected subjects with HBV/HCV co-infection and 44 pediatric comparators with HIV mono-infection was carried out in Henan Province of China from September 2011 to September 2012. All patients received HAART for 1-year. HBV and HCV infection was determined by antibody tests. HIV RNA load, CD4+ T-cell counts and liver function were determined before and after HAART. The Student's t-test or a one-way ANOVA was used for normally distributed values and A Mann-Whitney U-test was performed for values without normal distribution using SPSS statistical package 18.0 (SPSS Inc.). Results: After HAART for 1-year, the median levels of viral load were decreased to lower limit of detection in 90.34% pediatric HIV-infected subjects with/without HBV/HCV co-infection (P < 0.001), and CD4+ T-cell counts increased significantly (P < 0.001). Compared with the pre-HAART, mean level of alanine aminotransferase (ALT) in each group had a significant increase after HAART (P < 0.01). The mean levels of ALT and aspartate aminotransferase (AST) in nevirapine (NVP) based HAART group increased significantly after HAART (P < 0.01). Mean change values of ALT and AST were significantly higher in the NVP based regimen group than in the efavirenz (EFV) based regimen group (P < 0.01). For HIV/HBV/HCV co-infected patients, mean change values of ALT and AST in NVP-based HAART group was significantly higher than that in EFV-based HAART group (P < 0.01). Conclusion: Highly active antiretroviral therapy can damage liver function in pediatric HIV-infected subjects, especially in those with HBV/HCV co-infection. NVP was more harmful to liver function of pediatric HIV-infected subjects than EFV.
HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients

Song Yang,Huichun Xing,Yuming Wang,Jinlin Hou,Duande Luo,Qing Xie,Qin Ning,Hong Ren,Huiguo Ding,Jifang Sheng,Lai Wei,Shijun Chen,Xiaoling Fan,Wenxiang Huang,Chen Pan,Zhiliang Gao,Jiming Zhang,Boping Zhou,Guofeng Chen,Mobin Wan,Hong Tang,Guiqiang Wang,Yuxiu Yang,Dongping Xu,Peiling Dong,Qixin Wang,Jue Wang,Fernando A. Bognar,Daozhen Xu,Jun Cheng

DOI: https://doi.org/10.1186/s12985-016-0640-1

IF: 5.916

2016-01-01

Virology Journal

Abstract:Background This study aimed to evaluate the predictive values of hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) levels in 171 Chinese patients with chronic hepatitis B who received a 48-week course of pegylated interferon alfa-2b therapy at 1.5 mcg/kg. Methods HBsAg, HBeAg, and hepatitis B virus (HBV) DNA levels were measured at baseline and weeks 12, 24, 48, and 72. Clinical responses were defined as a combined response (CR, HBeAg seroconversion [sustained response, SR] combined with HBV DNA level <2,000 IU/mL at week 72). The positive predictive value and negative predictive value were calculated for HBsAg alone and/or combined with HBeAg and HBV DNA at weeks 12 and 24. Results Of 171 patients included, 58 (33.9 %) achieved a SR. Of patients who achieved a SR, 33 (56.9 %) achieved a CR. Totally 19.3 % (33/171) patients achieved CR and 80.7 % (138/171) patients did not. Patients with HBsAg <1500 IU/mL at week 12 had a 47.4 % chance of achieving an off-treatment SR and patients with a HBsAg decrease >1.5 logIU/mL at week 12 had a 54.5 % chance. Patients with HBsAg >20,000 IU/mL at weeks 12 and 24 had a 93.8 and 100.0 % chance, respectively, of not achieving a CR. An HBsAg level or changes at weeks 12 and 24, combined with HBeAg or HBV DNA, increased the chance for a SR and CR. Conclusions On-treatment HBsAg quantification, alone or in combination with HBeAg or HBV DNA, predicted off-treatment SR and CR after 48 weeks of PEG-IFNα-2b therapy, and thus, may guide clinicians in making a therapeutic decision to continue or terminate the therapy.
Age Versus Clinical Virological Characteristics In Chronic Hepatitis B Virus Infection: A Case Series Study In China

Dian-Lei Wu,Guang-Hua Xu,She-Min Lu,Bo-Lin Ma,Nai-Zhou Miao,Xiao-Bin Liu,Ji-Hong Feng,Na Liu,Qing-Lei Zeng,Wei-Kun Hou,Lei Pei,Yingren Zhao

DOI: https://doi.org/10.1097/MEG.0b013e32834fbf35

2012-01-01

European Journal of Gastroenterology & Hepatology

Abstract:Objectives This study aimed to investigate the clinical virological characteristics of hepatitis B virus (HBV) in chronic HBV infection patients of different ages, especially in relapse patients and patients with immune clearance.Methods The HBV clinical virological characteristics of chronic HBV infection were investigated in 1572 Chinese patients of different age groups (<20, 20-40, and >40 years old).Results Of the patients in the below 20 age group, those with evidence of immune tolerance accounted for 86.05% (P<0.001). Of the patients in the 20-40 age group, those with immune clearance accounted for 36.36% (P<0.001). Of the patients in the above 40 age group, there were markedly more reactivation cases than in any other group (P<0.001). Our data indicated that a positive correlation (r=0.480, P<0.001) existed between HBV DNA contents (on a log(10) scale) and the alanine aminotransferase (ALT) level of the total cases with reactivation. Of the 300 cases with immune clearance being followed up 10-50 months after enrollment, 181 cases achieved spontaneous hepatitis B e antigen (HBeAg) seroconversion (HBeAg to anti-HBe), and the younger the patient, the shorter the time to seroconversion (P<0.05).Conclusion Generally, there were significantly different HBV clinical virological characteristics in patients with chronic HBV infection of different ages. Different features were observed in relapse patients and patients with immune clearance at different ages, and these two types of patients needed antiretroviral therapy. Our study suggests that revisions of the timing and elevated alanine aminotransferase standards for chronic hepatitis B antiretroviral therapy in Chinese relapse patients and patients with immune clearance in different age groups are warranted. Eur J Gastroenterol Hepatol 24: 406-413 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon.

Feng-Qin Hou,Liu-Wei Song,Quan Yuan,Lin-Lin Fang,Sheng-Xiang Ge,Jun Zhang,Ji-Fang Sheng,Dong-Ying Xie,Jia Shang,Shu-Huan Wu,Yong-Tao Sun,Shao-Feng Wei,Mao-Rong Wang,Mo-Bin Wan,Ji-Dong Jia,Guang-Han Luo,Hong Tang,Shu-Chen Li,Jun-Qi Niu,Wei-Dong Zhou,Li Sun,Ning-Shao Xia,Gui-Qiang Wang

DOI: https://doi.org/10.7150/thno.10636

IF: 11.6

2015-01-01

Theranostics

Abstract:A recent study revealed that quantitative hepatitis B core antibody (qAnti-HBc) level could serve as a novel marker for predicting treatment response. In the present study, we further investigated the predictive value of qAnti-HBc level in HBeAg-positive patients undergoing PEG-IFN therapy. A total of 140 HBeAg-positive patients who underwent PEG-IFN therapy for 48 weeks and follow-up for 24 weeks were enrolled in this study. Serum samples were taken every 12 weeks post-treatment. The predictive value of the baseline qAnti-HBc level for treatment response was evaluated. Patients were further divided into 2 groups according to the baseline qAnti-HBc level, and the response rate was compared. Additionally, the kinetics of the virological and biochemical parameters were analyzed. Patients who achieved response had a significantly higher baseline qAnti-HBc level (serological response [SR], 4.52±0.36 vs. 4.19±0.58, p=0.001; virological response [VR], 4.53±0.35 vs. 4.22±0.57, p=0.005; combined response [CR], 4.50±0.36 vs. 4.22±0.58, p=0.009)). Baseline qAnti-HBc was the only parameter that was independently correlated with SR (p=0.008), VR (p=0.010) and CR(p=0.019). Patients with baseline qAnti-HBc levels ≥30,000 IU/mL had significantly higher response rates, more HBV DNA suppression, and better hepatitis control in PEG-IFN treatment. In conclusion, qAnti-HBc level may be a novel biomarker for predicting treatment response in HBeAg-positive patients receiving PEG-IFN therapy.
Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

Qiao-rong GAN,Chen PAN,Rui ZHOU,Ming-hua LIN,Li CHEN,Chun LIN,Cai-wen LIN,Qin LI,Jian-rong HUANG

DOI: https://doi.org/10.3760/cma.j.issn.1674-2397.2012.04.008

2012-01-01

Abstract:Objective To investigate the optimal therapy for patients with acute-on-chronic liver failure induced by hepatitis B.Methods A total of 302 patients with acute-on-chronic liver failure induced by hepatitis B in the Affiliated Infectious Diseases Hospital of Fujian Medical University were enrolled during January 2008 to January 2010.Patients were divided into group A ( medical treatment,n =57 ),group B (medical + antiviral treatment,n =80),group C ( medical + antiviral + artificial liver support system (ALSS),n =124) and group D (medical + antiviral + ALSS + traditional Chinese medicine treatment,n =41 ).Liver and renal function,prothrombin activity (PTA) and HBV DNA load were observed at the baseline,week 1,4,8,12 and the end of the treatment.All groups were followed up for 48 weeks to observe the survival rates.Kruskal-Willis H test was used to compare the efficacies in four groups,and Cox proportional hazards regression model was used for survival analysis. Results There was no difference among four groups in curative effects at week 4 ( H =3.213,P =0.360 ),but there was significant difference at week 12 (H =8.722,P =0.033).The one-year mortality rates for groups A,B,C,D were 36.84％ (21/57),32.50％ (26/80),26.61％ (33/124) and 24.39％ ( 10/41 ),respectively.The death risks of group C and D were 0.566 and 0.396 times of that in group B ( P =0.036 and 0.016).Conclusion Nucleoside analogue and ALSS plus medical treatment can effectively increase the survival rates of the patients with acute-on-chronic liver failure induced by hepatitis B.
Antiviral treatment standards for hepatitis B: An urgent need for expansion

Zi-Hong Bao,Zhi-Kun Dai,Hao-Xian Tang

DOI: https://doi.org/10.3748/wjg.v30.i4.418

IF: 5.374

2024-01-28

World Journal of Gastroenterology

Abstract:The present letter to the editor is related to the review with the title “Past, present, and future of long-term treatment for hepatitis B virus.” Chronic hepatitis B (CHB) represents an important and pressing public health concern. Timely identification and effective antiviral therapy hold the potential to reduce liver-related mortality attributable to chronic infection with hepatitis B virus (HBV) substantially. However, the current global treatment rates for CHB remain conspicuously low, with the excessively stringent treatment criteria advocated by national CHB gui-delines being a contributing factor to these low rates. Nevertheless, recent strides in comprehending this malady and the emergence of novel antiviral agents prompt the imperative re-evaluation of treatment standards to extend the sphere of potential beneficiaries. An impending need arises for a novel paradigm for the classification of patients with CHB, the expansion of antiviral treatment eligibility for HBV-infected individuals, and even the streamlining of the diagnostic process for CHB to amplify cost-effectiveness and augment survival prospects.

gastroenterology & hepatology
Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments

Chen‐Pi Li,Ru‐Yin Tsai,Hui‐Chin Chang,Shuo‐Yan Gau

DOI: https://doi.org/10.1111/apt.17851

IF: 9.524

2024-01-22

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 59, Issue 4, Page 587-587, February 2024.

pharmacology & pharmacy,gastroenterology & hepatology
Genotype B And Younger Patient Age Associated With Better Response To Low-Dose Therapy: A Trial With Pegylated/Nonpegylated Interferon-Alpha-2b For Hepatitis B E Antigen-Positive Patients With Chronic Hepatitis B In China

Hong Zhao,Fuat Kurbanov,Mo‐Bin Wan,You‐Kuan Yin,Jun‐Qi Niu,Jin‐Lin Hou,Lai Wei,Gui‐Qiang Wang,Yasuhito Tanaka,Masashi Mizokami,Chong‐Wen Si

DOI: https://doi.org/10.1086/511042

IF: 20.999

2007-01-01

Clinical Infectious Diseases

Abstract:Background. Cost and clinically significant adverse effects are the major limiting factors of interferon (IFN) use in therapy for chronic hepatitis B virus (HBV) infection. A clinical trial was conducted in China to study the efficiency and clinical relevance of low-dose regimen of IFN treatment for chronic HBV infection and to reveal factors predicting sustained combined response.Methods. During a randomized, open-label control study, hepatitis B e antigen (HBeAg)-positive patients with chronic HBV infection (n = 230) were assigned to receive pegylated IFN-alpha-2b (1.0 mu g/kg) (n = 115) or IFN-alpha-2b 2b ( 3 MIU; n = 115) for a 24- week period. Sustained combined response was assessed 24 weeks after the completion of treatment.Results. The greater rate of HBeAg loss in the pegylated IFN-group (23%) was the only statistically significant difference between the 2 treatment arms observed at the end of follow-up. The results of the multivariate statistical analysis revealed that HBV genotype B and patient age ( <= 25 years) were 2 independent factors associated with sustained combined response. A total of 40% of patients with HBV genotype B aged <= 25-years achieved sustained combined response. Only 4 (1.7%) of 230 patients discontinued therapy because of clinically significant adverse effects.Conclusions. The choice of low-dose IFN regimen might be a relevant clinical option to reduce the cost and adverse effects of therapy for younger patients with chronic HBV infection and genotype B infection in countries where it is prevalent.

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B ‐ authors' reply

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B

The Impact of Early Rapid Virological Response on the Outcomes of Hepatitis B Associated Acute on Chronic Liver Failure During Antiviral Treatment

Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B.

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments—Authors' reply

Efficacy and safety of interferon alpha therapy in children with chronic hepatitis B: A long-term follow-up cohort study from China.

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B

Association Between Negative Results from Tests for HBV DNA and RNA and Durability of Response after Discontinuation of Nucles(t)ide Analogue Therapy.

Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir

Editorial: baseline hepatitis B virus haplotype number may help predict a functional cure in patients with chronic hepatitis B treated with nucleotide analogues—authors' reply

Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan

Letter: improved alanine aminotransferase level in non-cirrhotic and low-viral load chronic hepatitis B patients treated with nucleotide/nucleoside analogues -authors' reply

Letter: Programmed Death-1-a Predictor for Antiviral Treatment in Chronic Hepatitis B. Authors' Reply.

The Effect of Highly Active Antiretroviral Therapy on Liver Function in Human Immunodeficiency Virus-Infected Pediatric Patients with or Without Hepatitis Virus Co-Infection

HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients

Age Versus Clinical Virological Characteristics In Chronic Hepatitis B Virus Infection: A Case Series Study In China

Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon.

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

Antiviral treatment standards for hepatitis B: An urgent need for expansion

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments

Genotype B And Younger Patient Age Associated With Better Response To Low-Dose Therapy: A Trial With Pegylated/Nonpegylated Interferon-Alpha-2b For Hepatitis B E Antigen-Positive Patients With Chronic Hepatitis B In China